The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. Dr. Baynes will be succeeded by Dr. Eliav Barr, effective April 1, 2022.

Clinical Development 52

Clinical Development Vaccine Research Laboratories Laboratories 52

The Pharma Data

JANUARY 24, 2021

(NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.

Vaccine 52

Vaccine Immune Response Virus Production 52

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Vaccine 52

Vaccine Virus Research Laboratories FDA 52

The Connected Lab

APRIL 29, 2020

When time is critical to the success of your laboratory’s mission, you need proven solutions that connect seamlessly and support your end-to-end workflow. Thermo Fisher Scientific’s integration capabilities can facilitate experiment creation and results export, providing a seamless connection to your LIMS or LIS.

Laboratories 52

Laboratories Vaccine Research Laboratories Production 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) approved VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

The Pharma Data

SEPTEMBER 1, 2021

Participants are not eligible for the trial if they have received the first dose of a COVID-19 vaccine more than seven days prior to enrollment, have previously had COVID-19 or are showing any signs or symptoms of COVID-19.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

The Pharma Data

MARCH 17, 2021

Davis, current executive vice president, global services and chief financial officer; as previously announced ( link ), Davis will become president of Merck, effective April 1, 2021, at which time the company’s operating divisions – Human Health, Animal Health, Manufacturing, and Merck Research Laboratories – will begin reporting to him.

Research Laboratories 52

Research Laboratories Laboratories Marketing Vaccine 52

The Pharma Data

NOVEMBER 5, 2021

The first global authorization of molnupiravir is a major achievement in Merck’s singular heritage of bringing forward advance drugs and vaccines to address the world’s topmost health challenges. As an oral remedial, molnupiravir offers an important addition to the vaccines and drugs stationed so far to fight the COVID-19 epidemic,” saidDr.

Licensing 52

Licensing Licensing Vaccine Laboratories 52

The Pharma Data

OCTOBER 26, 2021

Li, administrative vice chairman and chairman, Merck Research Laboratories. “ Li, administrative vice chairman and chairman, Merck Research Laboratories. “ Food and Drug Administration (FDA), and is laboriously working to submit operations to other nonsupervisory agencies worldwide.

Treatment 52

Treatment Government Vaccine Research Laboratories 52

The Pharma Data

SEPTEMBER 28, 2021

“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. About Merck.

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

Drug Discovery World

JANUARY 24, 2023

The researchers noted that such virtual trials incorporate numerous evidence-based assumptions regarding disease pathogenesis, therapeutic mechanism, side effects and a host of other factors which could impact the outcome. We’ve shown that this type of model can work.

Clinical Trials 242

Clinical Trials Trials Drugs Treatment 242

The Pharma Data

OCTOBER 23, 2021

Vicki Goodman, vice chairman, clinical exploration, Merck Research Laboratories. “ 10) have a new immunotherapy treatment option that can be used in combination with different chemotherapy agents.”. “ Now cases with metastatic TNBC who have excrescences that express PD-L1 (CPS ?

Treatment 52

Treatment Research Laboratories Trials Laboratories 52

The Pharma Data

JANUARY 17, 2021

Outlook The prevalence of COVID-19 across the globe has increased substantially since the trading update provided in November and Genus expects there will continue to be some challenges for our customers and employees for the remainder of our financial year, despite the prospect of better conditions as vaccines are being made available.

Research Laboratories 52

Research Laboratories Regulations Production Laboratories 52

The Pharma Data

JUNE 7, 2022

Li, president, Merck Research Laboratories. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

NOVEMBER 11, 2021

Joerg Koglin, vice chairman, Global Clinical Development and Therapeutic Area Head, Cardiovascular for Merck Research Laboratories. The inauguration of the Phase 3 VICTOR study reflects our commitment to chancing fresh options for a habitual heart failure condition that affects further than 3 million people in theU.S. About Merck.

Clinical Trials 40

Clinical Trials Hospitals Trials Research Laboratories 40

The Pharma Data

FEBRUARY 12, 2022

Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories. Lilly has licensed and developed bebtelovimab after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. About BLAZE-4.

Treatment 40

Treatment Hospitals FDA Clinical Trials 40

The Pharma Data

JULY 21, 2021

“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. The companies share equally the costs of the development of vericiguat. About Merck.

Treatment 52

Treatment Production Hospitals FDA Approval 52

Drug Discovery World

AUGUST 8, 2023

The India Brand Equity Foundation confirms that India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications 1. Outside of academia, there are institutions such as the CSIR- Central Drug Research Institute (CDRI), a multidisciplinary research laboratory in Lucknow 11.

Research 130

Research Pharmacy Pharmaceuticals Government 130

The Pharma Data

APRIL 16, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

JANUARY 20, 2021

We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

MARCH 15, 2022

“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Merck.

DNA 52

DNA Clinical Trials Trials Therapies 52

The Pharma Data

JANUARY 26, 2021

Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said the emergence of new variants of the virus calls for new strategies even while vaccination is ongoing in many parts of the world.

Virus 52

Virus Nurses Research Laboratories Trials 52

The Pharma Data

MARCH 8, 2021

“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories. “We Our Commitment to Infectious Diseases.

Trials 52

Trials Clinical Trials Pharmacokinetics Research Laboratories 52

The Pharma Data

NOVEMBER 18, 2021

For over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. About Merck.

Clinical Trials 52

Clinical Trials Trials Treatment RNA 52

The Pharma Data

JULY 21, 2021

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. About Merck.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

OCTOBER 25, 2021

Merck Research Laboratories. “ For over 130 times, Merck, known as MSD outside the United States and Canada, has been contriving for life, bringing forward drugs and vaccines for numerous of the world’s most grueling conditions in pursuit of our charge to save and ameliorate lives. About Merck.

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

OCTOBER 27, 2021

Joan Butterton, vice chairman, global clinical development, contagious conditions, Merck Research Laboratories. Gilead operates in further than 35 countries worldwide, with headquarters in Foster City, California. About Merck.

Treatment 52

Treatment Clinical Trials Clinical Development Research Laboratories 52

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Nature Neuroscience. Read You love to see it! Andreano E. Nature Communications.

DNA 52

DNA RNA Engineering Licensing 52

Codon

JULY 21, 2024

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” Work towards improving animal welfare is ongoing and certainly not limited to research laboratories.

Research 121

Research Engineering Science Laboratories 121

Codon

JUNE 30, 2024

Chakrabarty was working at the Research & Development Center at General Electric Company in Schenectady, New York when he engineered a Pseudomonas strain to eat oil in 1972, but his interest in these microbes began nearly half a decade earlier while a postdoctoral fellow at the University of Illinois. Credit: Matt H.

DNA 97

DNA Engineering Laboratories Production 97

The Pharma Data

APRIL 7, 2023

We remain fully committed to building on existing treatments as part of our efforts to help as many appropriate patients with cancer as we can,” said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. Senior Vice President, Clinical Development, Oncology at Eisai Inc.

Trials 40

Trials Clinical Trials Treatment Therapies 40

The Pharma Data

JANUARY 26, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

NOVEMBER 9, 2020

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

APRIL 4, 2023

For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. This expands the use of KEYTRUDA-based regimens to more patients with advanced urothelial carcinoma and demonstrates the value of collaboration in creating new combination approaches for patients in need of more options.”

Treatment 40

Treatment FDA Approval FDA Therapies 40

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. About Merck.

Trials 52

Trials Clinical Trials International Production 52

The Pharma Data

MARCH 11, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40